Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

43.51USD
18 Sep 2018
Change (% chg)

$0.50 (+1.16%)
Prev Close
$43.01
Open
$42.94
Day's High
$43.67
Day's Low
$42.83
Volume
5,940,669
Avg. Vol
6,240,662
52-wk High
$43.67
52-wk Low
$33.20

Latest Key Developments (Source: Significant Developments)

Allogene Therapeutics Files For IPO Of Up To $100 Million
Friday, 14 Sep 2018 

Sept 14 (Reuters) - Allogene Therapeutics::ALLOGENE THERAPEUTICS INC FILES FOR IPO OF UP TO $100 MILLION – SEC FILING.SAYS IT INTENDS TO APPLY TO HAVE ITS COMMON STOCK LISTED ON NASDAQ GLOBAL SELECT MARKET UNDER THE SYMBOL "ALLO".SAYS GOLDMAN SACHS & CO. LLC, J.P. MORGAN, COWEN ARE AMONG UNDERWRITERS TO IPO.SAYS JEFFERIES IS AMONG UNDERWRITERS TO IPO.PROPOSED IPO PRICE IS AN ESTIMATE SOLELY FOR CALCULATING SEC REGISTRATION FEE.SAYS PFIZER INC HAS 24.6 PERCENT HOLDING IN CO BEFORE THE IPO - SEC FILING.SAYS GILEAD SCIENCES INC HAS 8.4 PERCENT HOLDING IN CO BEFORE IPO.  Full Article

Pfizer Terminates Domagrozumab Clinical Studies For The Treatment Of Duchenne Muscular Dystrophy
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - Pfizer Inc ::PFIZER TERMINATES DOMAGROZUMAB (PF-06252616) CLINICAL STUDIES FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY.PFIZER INC - PHASE 2 STUDY (B5161002), DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT.PFIZER INC - STUDIES WERE NOT TERMINATED FOR SAFETY REASONS.PFIZER INC - EVALUATION OF TOTALITY OF EVIDENCE INCLUDING SECONDARY ENDPOINTS DID NOT SUPPORT A SIGNIFICANT TREATMENT EFFECT.PFIZER INC - PFIZER WILL CONTINUE TO REVIEW DATA.PFIZER INC - TERMINATING TWO ONGOING CLINICAL STUDIES EVALUATING DOMAGROZUMAB (PF-06252616).  Full Article

Exact Sciences CEO Expects Revenue Of About $700 Million In 2019
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES CEO SAYS PFIZER DEAL TO HAVE VERY LITTLE IMPACT ON COLOGUARD SALES IN 2018 - CONF CALL.EXACT SCIENCES EXPECTS REVENUE OF ABOUT $700 MILLION IN 2019 - CONF CALL.EXACT SCIENCES EXPECTS PFIZER DEAL TO HAVE IMPACT ON COLOGUARD SALES THROUGHOUT 2019 - CONF CALL.  Full Article

Therachon Raises $60 Million Mezzanine Financing
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Therachon AG::THERACHON RAISES $60 MILLION MEZZANINE FINANCING TO ADVANCE LEAD PROGRAM IN ACHONDROPLASIA AND TO EXPAND RARE DISEASE PIPELINE.THERACHON AG SAYS FINANCING LED BY NOVO HOLDINGS, JOINED BY COWEN HEALTHCARE INVESTMENTS, PFIZER VENTURES, AMONG OTHERS.  Full Article

Gemphire Announces Amended And Restated Gemcabene License Agreement With Pfizer
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE ANNOUNCES AMENDED AND RESTATED GEMCABENE LICENSE AGREEMENT WITH PFIZER INC..RESTATED LICENSE AGREEMENT WITH PFIZER COVERING GEMCABENE.GEMPHIRE THERAPEUTICS INC - AS AMENDED, PFIZER HAS RIGHT TO TERMINATE LICENSE IF FIRST COMMERCIAL SALE HAS NOT OCCURRED BY APRIL 2024.AMENDMENT INCLUDS EXTENDING DATE OF AGREED DEADLINE FOR FIRST COMMERCIAL SALE.  Full Article

Antares Pharma Enters Into Development Agreement With Pfizer
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Antares Pharma Inc ::ANTARES PHARMA ENTERS INTO DEVELOPMENT AGREEMENT WITH PFIZER INC..ANTARES PHARMA - PFIZER TO PAY FOR DEVELOPMENT OF PRODUCT, TO BE RESPONSIBLE FOR OBTAINING FDA APPROVAL OF COMBINATION PRODUCT.ANTARES PHARMA INC - CO, PFIZER TO DEVELOP A COMBINATION DRUG DEVICE RESCUE PEN.ANTARES PHARMA - ANTARES TO RECEIVE ROYALTIES ON NET SALES ON COMBINATION PRODUCT.  Full Article

Glycomimetics Says Pfizer Sees Top Line Data Available In Q2 For Ongoing Phase 3 Trial With Rivipansel
Wednesday, 25 Jul 2018 

July 25 (Reuters) - GlycoMimetics Inc ::GLYCOMIMETICS SAYS ON JULY 23, NOTIFIED BY PFIZER THAT PFIZER NOW SEES TOP LINE DATA AVAILABLE IN Q2 OF 2019 FOR ONGOING PHASE 3 TRIAL WITH RIVIPANSEL.  Full Article

Pfizer To Build Sterile Injectable Facility In Michigan
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Pfizer Inc ::PFIZER TO BUILD CUTTING-EDGE STERILE INJECTABLE FACILITY IN MICHIGAN, INVESTING NEARLY HALF A BILLION DOLLARS IN U.S. MANUFACTURING, CREATING MORE THAN 450 JOBS.DURING NEXT SIX YEARS, EXPECT TO INVEST ABOUT $1.1 BILLION IN KALAMAZOO COUNTY.WILL INVEST $465 MILLION INVESTMENT TO BUILD STERILE INJECTABLE PHARMACEUTICAL PRODUCTION FACILITIES IN PORTAGE, MICHIGAN.AFTER FACILITY IN PORTAGE VALIDATED BY REGULATORY AGENCIES PRODUCTION SHOULD BEGIN IN 2024.  Full Article

U.S. FDA Approves Pfizer’s Biosimilar Nivestym
Friday, 20 Jul 2018 

July 20 (Reuters) - Pfizer Inc ::U.S. FDA APPROVES PFIZER’S BIOSIMILAR NIVESTYM™ (FILGRASTIM-AAFI).U.S. FDA APPROVES PFIZER’S BIOSIMILAR NIVESTYM™ (FILGRASTIM-AAFI).  Full Article

Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Pfizer Inc ::PFIZER AND LILLY ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 TRIAL OF TANEZUMAB FOR THE TREATMENT OF OSTEOARTHRITIS (OA) PAIN.PFIZER AND LILLY ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 TRIAL OF TANEZUMAB FOR THE TREATMENT OF OSTEOARTHRITIS (OA) PAIN.PFIZER - STUDY DEMONSTRATED THAT PATIENTS WHO RECEIVED 2 DOSES OF TANEZUMAB SEPARATED BY EIGHT WEEKS EXPERIENCED A STATISTICALLY SIGNIFICANT IMPROVEMENT.PFIZER INC - PRELIMINARY SAFETY DATA SHOWED THAT TANEZUMAB WAS GENERALLY WELL TOLERATED.PFIZER INC - THERE WERE NO EVENTS OF OSTEONECROSIS OBSERVED IN TRIAL;NO NEW SAFETY SIGNALS WERE IDENTIFIED.PFIZER INC - STUDY MET ALL THREE CO-PRIMARY ENDPOINTS.PFIZER INC - DURING STUDY, ABOUT 1% OF PATIENTS HAS TO DISCONTINUE TREATMENT DUE TO ADVERSE EVENTS.PFIZER - RAPIDLY PROGRESSIVE OSTEOARTHRITIS OBSERVED IN TANEZUMAB-TREATED PATIENTS AT FREQUENCY OF LESS THAN 1.5%, & WAS NOT OBSERVED IN PLACEBO ARM.  Full Article

PRESS DIGEST- British Business - Sept 18

Sept 18 The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.